TESARO Inc (NASDAQ:TSRO) has received an average rating of “Buy” from the twenty-eight brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation, fourteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $133.14.
TSRO has been the subject of a number of research reports. Credit Suisse Group reissued an “outperform” rating and set a $150.00 price objective (down previously from $190.00) on shares of TESARO in a research report on Thursday, January 18th. Barclays reduced their price objective on TESARO from $135.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 28th. Cowen reduced their price objective on TESARO from $125.00 to $80.00 and set a “market perform” rating for the company in a research report on Tuesday, January 2nd. BidaskClub raised TESARO from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 23rd. Finally, Morgan Stanley reduced their price objective on TESARO from $165.00 to $156.00 and set an “overweight” rating for the company in a research report on Tuesday, January 16th.
Shares of TSRO stock opened at $59.75 on Friday. The company has a market capitalization of $3,349.68, a price-to-earnings ratio of -6.50 and a beta of 1.40. The company has a quick ratio of 4.39, a current ratio of 4.74 and a debt-to-equity ratio of 1.75. TESARO has a 12-month low of $52.20 and a 12-month high of $168.92.
TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.96). The firm had revenue of $48.02 million for the quarter, compared to analyst estimates of $51.78 million. TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. research analysts expect that TESARO will post -9.54 EPS for the current year.
In other TESARO news, SVP Orlando Oliveira sold 3,000 shares of the firm’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $69.88, for a total transaction of $209,640.00. Following the transaction, the senior vice president now directly owns 9,076 shares in the company, valued at $634,230.88. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Leon O. Moulder, Jr. bought 5,000 shares of the business’s stock in a transaction on Friday, March 2nd. The shares were bought at an average price of $56.93 per share, for a total transaction of $284,650.00. Following the completion of the acquisition, the chief executive officer now owns 1,018,828 shares of the company’s stock, valued at $58,001,878.04. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 334,913 shares of company stock worth $19,083,294 and have sold 13,042 shares worth $760,526. 34.60% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Toronto Dominion Bank increased its stake in shares of TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares during the period. Commonwealth Equity Services Inc bought a new position in shares of TESARO in the third quarter worth about $222,000. Crossmark Global Holdings Inc. bought a new position in shares of TESARO in the third quarter worth about $230,000. CIBC Asset Management Inc bought a new position in shares of TESARO in the third quarter worth about $234,000. Finally, Exane Derivatives increased its stake in shares of TESARO by 137.1% in the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 1,123 shares during the period.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/03/21/tesaro-inc-tsro-receives-133-14-consensus-pt-from-brokerages.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.